Location:
Level 6, Seminar Room Wallace Wurth Building UNSW Australia Sydney NSW 2052
Open to
All
Contact for enquiries
Rata Joseph +61 (0)2 9385 0900 rjoseph@kirby.unsw.edu.au
The Kirby Institute is pleased to present:
Professor Greg Dore - Kirby Institute
"Broad access to interferon-free HCV therapy: an opportunity for Australia to be a world leader."
Tuesday 9th February 2016
Seminar: 1pm-2pm
Abstract:
The PBS listing in March 2016 of highly effective interferon-free HCV regimens, including the lack of liver disease stage or drug and alcohol restrictions, provides Australia with the opportunity to turnaround the escalating burden of HCV-related liver disease. Strategies to enhance HCV treatment uptake among people who inject drugs will be crucial to achieve population-level impact, including potential for HCV treatment as prevention.
Bio:
Professor Gregory Dore is Head of the Viral Hepatitis Clinical Research Program, Kirby Institute for infection and immunity in society, The University of New South Wales and an Infectious Diseases Physician at St Vincent’s Hospital, Sydney. He has been involved in the HIV and hepatitis C sectors for 20 years, in academic research, clinical, and public health policy capacities.
Professor Dore’s major research work has been in the areas of hepatitis C natural history, and therapeutic strategies. In the area of clinical research, he has led studies in acute and chronic hepatitis C, particularly for people who inject drug and individuals on opiate agonist therapy.
He is a NHMRC Practitioner Fellowship, Past President of the Australasian Society for HIV, Viral Hepatitis and Sexual health Medicine (ASHM), and recently completed a three-year term on NHMRC Council.
Professor Dore established the St Vincent’s Hospital Hepatitis Clinic in 1999 and has led development of the hepatitis C clinical service into one of Australia’s leading services.